Kornimate/medical-research-clean huggingface dataset:
a 4 year combination therapy of growth hormone and (gnrh) agonist in children with a short predicted height

Conditions: Idiopathic Short Stature

Summary: estrogens are responsible for the disappearance of growth cartilage in the long bones at the end of the pubertal growth spurt both in boys and in girls. it is therefore hypothesized that stopping pubertal development and hence estrogen production, will prolong and increase the pubertal growth spurt, especially when growth hormone is given concommitantly. boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a predicted height under 151 cm will be treated with triptorelin 3.75 mg and zomacton growth hormone for 4 years.


Eligibility criteria:
inclusion criteria: * adult height prediction below -2.5 sd : 151 cm for girls and 164 cm for boys based on the vlaamse groeicurve 2004 (vub.ac.be/groeicurven) * pubertal: breast development at least m2 for girls and at least 4 ml of testicular volume for boys * bone age \>10 years but \ 11 but \< 13 years for boys * signed informed consent exclusion criteria: * adopted children ( different genetic background, lack of data on birth parameters and parents) * bone dysplasia or sitting height/ total height \> 2 sds on standards by gerver et al (see appendix) * chronic use of glucocorticoids * previous growth promoting therapy such as gh, sex steroids, oxandrolone, * known gh deficiency * chronic infectious disease * active rheumatic disease * previously diagnosed or currently suspected malignancy * sex steroid therapy * diabetes mellitus * renal insufficiency (serum creatinine \> 1.5 mg/dl) * hepatic disease ( liver test \> 4 fold upper limit of normality) * current congestive heart failure * inability to follow the study protocol * treatment with a non registered drug during the last 30 days before the moment of inclusion.

Keywords: gonadotropin releasing hormone agonist growth hormone final height bone density puberty
superior cluneal nerve entrapment syndrome, kinesiotaping and myofascial release techniques

Conditions: Superior Cluneal Nerve Entrapment

Summary: myofascial release techniques and/or kinesiotaping may be effective in the treatment of superior cluneal nerve impingement syndrome ?


Eligibility criteria:
inclusion criteria: * patients diagnosed with superior cluneal nerve entrapment syndrome exclusion criteria: * those with communication problems * those who also described pain in the mid-lumbar region
risk factors for falls after intervention of the urgent medical assistance service (samu) in the elderly person at home

Conditions: Elderly

Summary: in this project, the investigators are interested in a particular population, that of elderly subjects who used the samu after a fall and who are not hospitalized or are hospitalized less than 24 hours. the scientific literature concerning this population is poor . however, this is a particularly vulnerable population. the direction of research, studies, evaluation and statistics (drees) report notes that in 2005 in metropolitan france, 24% of people aged 65 to 75 said they had fallen in the last 12 months. home falls among seniors may require emergency medical services (ems).

the first cause of accidental death in people over 65, the fall often has a pejorative impact on the physical, psychological and quality of life . it is also predictive of entry into an institution. in this project, the investigators propose to evaluate the patient at home with a gerontological assessment nurse working in collaboration with the attending physician, whenever the fall triggers a call to the samu (without hospitalization or with hospitalization of less than 24 hours). in addition to the evaluation, the nurse will propose a personalized intervention plan (pip) based on targeted and prioritized actions. the main objective is to study the effect of a personalized intervention plan (pip) proposed by a gerontological assessment nurse at home in the elderly who used the samu for a fall (with on-site care or hospitalization inferior to 24h), on the delay institutionalization or death before institutionalization compared to standard care.

Eligibility criteria:
inclusion criteria: * living at home * living at maximum 45 minutes from a hospital center participating in the study (for logistical reasons and practices of study organization) * intervention of the samu for a fall at home without there being hospitalization or with hospitalization lasting less than 24h * patient or trusted person capable of giving telephone information * patient or his / her trusted person who has agreed to participate in the study * patient affiliated to a social security scheme exclusion criteria: * total dependency (adl at 0) * entry in nursing home already scheduled within 3 months

Keywords: risks factors fall patients elderly urgent medical assistance service emergency care 911
retrospective evaluation of plane blocks in laparoscopic cholecystectomy

Conditions: Postoperative Pain

Summary: the investigators use usually a plane block for postoperative analgesia; if it suitable. i̇n laparoscopic patients; investigators used oblique subcostal transversus abdominis plane block; formerly. but in the last few months, the investigators have performed serratus intercostal (brilma) block with bilateral rectus sheath block. in this retrospective evaluation, the aim of the retrospective evaluation is to determine the effects of two block on postoperative opioid consumption.


Eligibility criteria:
inclusion criteria: * patients undergoed laparoscopic cholecystectomy asa i-ii-iii exclusion criteria: * patients used another block or block combination * no block performed patients * procedure converted to open procedure
the use of remote monitoring to improve patient-reported outcomes and readmission rates following radical cystectomy

Conditions: Bladder Cancer; Quality of Life

Summary: following radical cystectomy for bladder cancer, nearly two-thirds of patients experience a complication and almost a third are readmitted. thus, intensified monitoring of this vulnerable group represents an opportunity for improved quality of care in the post-operative setting. by gathering biomarkers passively and continuously, wearable activity monitors augment remote patient monitoring. further, they facilitate the collection of patient-reported outcomes frequently. despite the proven impact of remote monitoring on patient care, there is limited data on the feasibility and impact of employing this technology to trigger real-time provider assessment following cystectomy. the investigators plan to conduct a randomized control trial examining such. the intervention group of participants will receive continuous biomarker monitoring via fitbits and daily patient-reported outcome assessments via connected smartphones. abnormalities in remote data will trigger automated alerts to providers. providers will respond in real-time to these alerts and patients will receive education materials discussing preventative measures to mitigate the main risk factors for readmissions. the investigators will evaluate the feasibility of integrating this technology into the post-operative period, as well as the impact of real-time provider attention to abnormal remote data on patient-reported outcomes and rates of readmission. the investigators hypothesize that early assessment of and intervention on remote abnormalities will promote the use of outpatient or reduced intensity therapies, such as oral antibiotics or oral hydration, thus curtailing the severity of patient symptoms, intensity of complications, and need for hospitalizations. ultimately, this trial builds upon prior research, applying patient-centered technology to improve the quality of care following cystectomy.


Eligibility criteria:
inclusion criteria: * undergoing cystectomy at three hospitals within the university of pittsburgh medical center system * english speaking * owns smart phone exclusion criteria: * unwilling or unable to participate * non-english speaking * does not own smart phone

Keywords: bladder cancer remote monitoring quality of life cystectomy
effects of combined cognitive training and rhythmic auditory stimulation in treadmill training after stroke

Conditions: Stroke

Summary: the objective of this study is to compare the effects of progressive combined cognitive training and rhythmic auditory stimulation to treadmill training (combined group), cognitive treadmill training (cognitive group), rhythmic auditory stimulation to treadmill training (rhythmic group), and treadmill walking alone (treadmill group) on walking automaticity, executive function, and dual-task coordination for patients with chronic stroke (aim 1). the second aim of this study is to investigate the factors affecting the results of interventions (aim 2). the third aim of the study is to examine the characteristics of stroke population who are appropriate for progressive combined cognitive training and rhythmic auditory stimulation to treadmill training.

a single-blinded, randomized controlled trial will be conducted at medical centers. eighty stroke patients will be randomized to one of the four groups. all groups will receive interventions 30 minutes per time, 3 times a week, for 4 weeks. the combined group will undertake progressive treadmill walking speed and rhythmic auditory stimulation while performing a cognitive task. the cognitive group will receive cognitive training while walking on the treadmill. the rhythmic group will hear rhythmic auditory stimulation while treadmill walking. the treadmill group will train only in progressive treadmill walking. a blinded assessor will administer three assessments. all participants will be examined for gait and cognitive performance under single-task (walking only, stroop task only) and dual-task conditions (walking while performing the stroop task) at baseline, post-intervention, and one-month follow-up. the primary outcome measures of gait and cognition are gait speed and cognitive score of the stroop task under single- and dual-task conditions. the secondary outcome measures are the mini-bestest, walking ability questionnaire, 6-minute walk test, and stroke impact scale. repeated measure anova will be used to compare measurements at baseline, after training, and follow-up between and within the groups.

Eligibility criteria:
inclusion criteria: 1. diagnosed with first-time stroke; 2. more than 6 months after stroke onset; 3. able to walk 10 meters; 4. no severe vision, hearing, or speech impairments; 5. understand and follow the instructions and sign the informed consent form; 6. older than 20 years old. exclusion criteria: 1. orthopedic problems affecting walking or other diseases that may interfere with study participation; 2. a score of less than 24 on the mini-mental state examination (mmse); 3. severe balance disorder with a total score of less than 45 points berg balance scale.

Keywords: stroke gait rehabilitation rhythmic auditory stimulation cognitive training
the effect of exercise on individuals with parkinson's disease

Conditions: Parkinson's Disease

Summary: the goal of this trial is to compare the effect of two different exercise programs on neuro-physiological, motor, functional, and quality-of-life issues in individuals with parkinson's disease to determine which program is most beneficial.

parkinson's disease (pd) negatively affects the quality of life for a million individuals in the united states. while medication and surgery are the most effective treatments for pd, physicians and people with pd often delay using these treatments because of their considerable adverse side effects. until a cure for pd is discovered, there is a compelling need to develop interventions that provide relief of symptoms without causing negative side effects. recent research suggests that exercise may provide symptom relief in some characteristics of pd. while various exercise interventions appear to effectively improve motor, functional, and quality-of-life issues, the research is mixed regarding the nature, extent and duration of these improvements. understanding how multiple characteristics of pd change and whether they can be modified by different exercise programs is essential to determining if an exercise program is clinically effective for pd. this study is designed to compare the initial (six months), and then long-term (2 years) effect that 2 different exercise programs (progressive resistance program or flexibility program) have on neuro-physiological, motor, functional, and quality-of-life issues in individuals with parkinson's disease. the goal is to determine which program is most beneficial. results from this study will be used to determine which exercise program produces the most beneficial effects on neuro-physiological, motor, functional and quality-of-life measures. note: recruitment for parkinson's disease participants is now closed.

Eligibility criteria:
inclusion criteria: * a diagnosis of pd * up to the age of 67 * on at least 1 da drug, may be on several pd medications * able to walk for six minutes (may take rest breaks) * able to come off their pd medication for testing (12 hour overnight withdrawal of antiparkinsonian medications) * able to stay on stable pd medications for at least 6 months * live within a 30 mile radius of chicago * hoehn and yahr score: ii - iii while in the "off" pd medication state exclusion criteria: * history of any other neurological disorder as determined by medical history and neurological exam * history of a known injury, disease, or other disorder that might interfere with motor function in the proposed experiments * a score less than 23 on the mini-mental state examination * currently involved in an active, ongoing formal exercise program deep brain stimulation surgery * known cardiac problem or significant hypertension * depression that may interfere with regular exercise * hallucinations or being treated for hallucinations

Keywords: parkinson's disease exercise
a study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (vit-b) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin

Conditions: Refractory Solid Tumors in Children

Summary: this phase i study is designed to determine the maximum tolerated dose of irinotecan given intravenous for 5 days every 3 weeks in combination with fixed doses of vincristine, temozolomide and bevacizumab (vit-b) in patients with refractory solid tumors.


Eligibility criteria:
inclusion criteria: * age: patients must be \> 12 months and \< 21 years of age at the time of study entry. * weight: patient must be more than or equal to 10 kilograms. histological diagnosis: * patients must have had histological verification of the malignancy at some time prior to study entry. * all solid tumors are eligible with the exclusion of lymphomas. for patients with neuroblastoma, diagnosis based on elevated catecholamines in the urine and tumor cells on bone marrow aspirates/biopsies is acceptable. * for patients with germ cell tumors, diagnosis based on elevated tumor markers (serum alpha fetoprotein and/or serum beta human chorionic gonadotropin) and radiographic evidence of disease is acceptable. disease status: * disease must have failed standard therapy (therapies) or be a disease for which no standard therapy exists. * patient with stable disease on other therapies are not eligible. performance level: * karnofsky \> 50% for patients \>16 years of age and lansky \> 50 for children \< 16 years of age (appendix i). * life expectancy: must be \> 8 weeks. exclusion criteria: * patients who have received bevacizumab and/or irinotecan previously are ineligible. non brain tumor patients who have previously received temozolomide are ineligible. * pregnancy or breast-feeding: pregnant patients are ineligible for this study due to the known teratogenic effects of the cytotoxic agents. pregnancy tests must be obtained in females of childbearing potential prior to enrollment. * lactating women must agree not to breast-feed. * males or females of reproductive age may not participate unless they have agreed to use an effective contraceptive method. * patients who have an uncontrolled infection will not be eligible for enrollment until all infections are under control. * clinically significant unrelated systemic illness: patients with serious infections or significant pulmonary, hepatic, renal, or other end-organ dysfunction which in the judgment of the principal or co-investigators would compromise the patient's ability to tolerate prescribed chemotherapy or are likely to interfere with the study procedures or results will not be eligible.
efficacy and tolerability of nm-bl in patients with exocrine pancreatic insufficiency due to cystic fibrosis

Conditions: Pancreatic Insufficiency; Cystic Fibrosis; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases

Summary: the purpose of this randomized, double-blind, multicenter, two-period crossover study is to assess the efficacy and tolerability of burlulipase (nm-bl) in patients with exocrine pancreatic insufficiency due to cystic fibrosis


Eligibility criteria:
inclusion criteria: * male and female patients aged ≥12 years from the date of informed consent * confirmed diagnosis of cf at screening * confirmed epi by historical (within past 12 months) cfa \<70% without use of perts or current fecal elastase \<50 µg/g stool at screening * currently receiving pert with a commercially available pancreatic enzyme * currently on stable treatment with proton pump inhibitors or h2 receptor antagonists * clinically stable condition without evidence of acute respiratory disease or any other acute condition exclusion criteria: * history of fibrosing colonopathy * history of significant bowel resection, in the opinion of the investigator, or solid organ transplant * history of being refractory to pancreatic enzyme replacement * current diagnosis or history of distal intestinal obstruction syndrome * current diagnosis of small intestinal bacterial overgrowth, ileus or acute abdomen * a body mass index percentile \<10%
efficacy and safety of ranibizumab in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia

Conditions: Pathological Myopia

Summary: this study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin pdt in patients with visual impairment due to choroidal neovascularization (cnv) secondary to pathologic myopia (pm).


Eligibility criteria:
inclusion criteria: * visual impairment due to choroidal neovascularization (cnv) secondary to pm * best corrected visual acuity (bcva) in the study eye \> 24 and \< 78 early treatment diabetic retinopathy study (etdrs) letters * high myopia (\> -6d), anterior-posterior elongation \> 26 mm; posterior changes compatible with the pathologic myopia * either lesion types in the study eye: subfoveal, juxtafoveal, extrafoveal exclusion criteria: * patients with uncontrolled systemic or ocular diseases * blood pressure \> 150/90 mmhg * history of pan-retinal, focal/grid laser photocoagulation or intraocular treatment with any anti-vegf or vpdt in the study eye * intravitreal treatment with corticosteroids or intraocular surgery within last 3 months in the study eye other protocol-defined inclusion/exclusion criteria may apply

Keywords: pathologic myopia pm choroidal neovascularization cnv ranibizumab verteporfin pdt
study of new magnetic resonance methods

Conditions: Healthy

Summary: this study will evaluate new magnetic resonance imaging (mri ) methods using a mri machine more powerful than those in most hospitals. mri is a diagnostic tool that uses a large magnet and radio waves to produce images of the human body. it can also provide information about brain chemistry and physiology. this study will use the new mri hardware and methods to measure blood flow and metabolism in regions of the brain during simple tasks, such as listening to tones or watching flashing checkerboards. healthy normal volunteers will undergo mri scanning. for this procedure, the person lies on a stretcher that is moved into a mri machine, which produces a strong magnetic field. a special lightweight coil is placed on the person's head to obtain better pictures. the scan time ranges from 20 minutes to 2 hours, with the average scan lasting between 45 and 90 minutes. during the mri, the person may be asked to perform simple tasks, such as listening to tones or watching a screen, tapping fingers or moving a hand. more complex tasks may require thinking about tones or pictures and responding to them by pressing buttons. the images produced in this study will be compared with those produced using standard mri. the results will be used to develop improved imaging methods for better patient care and research.

technical advances in magnetic resonance imaging (mri) and magnetic resonance spectroscopy (mrs) has provided researchers with the opportunity to study functional and metabolic changes of the central nervous system (cns) in both healthy controls and individuals with neurological diseases in response to sensory, motor or cognitive stimulation. while mri is in common usage in radiology departments and clinics mri and mrs techniques and hardware are continually being upgraded and designed for functional magnetic resonance imaging (fmri) and magnetic resonance spectroscopic imaging of the cns at 3.0 tesla. we will evaluate new sequences on volunteers and for potential use in patients with cns pathology. these studies are required in order to develop and implement new imaging techniques for research and clinical applications.

Eligibility criteria:
* inclusion criteria: 1. age 18 and older 2. capable of providing own informed consent 3. capable of filling out mri screening form exclusion criteria: 1. contraindications for mri including aneurysm clip; implanted neural stimulator; implanted cardiac pacemaker or auto-defibrillator; cochlear implant; ocular foreign body (e.g. metal shavings); or insulin pump, or other metal in the body. 2. pregnancy 3. subjects will be excluded if it is deemed that they have a condition that would preclude their participation for technical development (e.g. claustrophobia) 4. subjects will be excluded if they present unnecessary risk (e.g. brain surgery of uncertain type, etc.).

Keywords: mri/mrs functional mri metabolic imaging brain healthy volunteer
acqmap® us registry of procedural and long-term clinical outcomes (discover-us)

Conditions: Ablation of Arrhythmia's

Summary: acqmap registry is an observation study

acqmap registry is an observational, prospective, multi-center, open-label registry designed to provide clinical data regarding the commercial, real-life experience with the diagnostic acqmap system.

Eligibility criteria:
inclusion criteria: male or female 18 years of age or older. currently scheduled for an ablation of an arrhythmia utilizing the diagnostic acqmap system. willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study. willing and able to give written informed consent. exclusion criteria: in the opinion of the investigator, any known contraindications to an ablation procedure. current enrollment in any study protocol sponsored by acutus medical. any other condition that, in the judgment of the investigator, makes the participant a poor candidate for this procedure, the study, or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, extensive travel away from the research center, etc.).

Keywords: ablation atrial arrhythmia